Agenus Inc., an immuno-oncology company with a pipeline of therapeutics designed to activate the immune response to cancers and infections, has entered into three new clinical collaborations with Targovax, Oxford BioTherapeutics, and Immunogenesis, doubling its current number of clinical collaborations.
The parties have entered into a collaboration agreement to develop Targovax´s TG mutant KRAS cancer vaccines in combination with Agenus´s QS-21 STIMULON adjuvant technologyThe agreement may be...
Oslo, 17 January 2022: Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announce that patents no CN108495934 and JP6974350 have been granted by the Chinese and Japanese Patent Offices, respectively. The patents cover the use of ONCOS-102 in combination with chemotherapy in malignant mesothelioma.
Targovax ASA, a clinical stage immuno-oncology company, announces that Innovation Norway has awarded Targovax an NOK 8.2 million grant to accelerate product development activities related to the company’s TG mutant RAS vaccine programme and planned clinical trials.
OSLO, Norway, Oct. 20, 2021 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces the appointment of Dr. Erik Digman Wiklund as Chief Executive Officer (CEO). Dr. Wiklund has intimate knowledge of the company and its technology having served as Chief Business Officer (CBO) and Chief Financial Officer (CFO) of Targovax since 2017.
Targovax ASA appointed Ola Melin as Head of Manufacturing. He will take a leading role in driving Targovax's Chemistry, Manufacturing, and Controls (CMC) program forward. Ola will be a member of Targovax's management team.
Targovax ASA, a clinical stage immuno-oncology company, announce that the European Patent Office has granted EU Patent no EP3402889. The patent covers the use of ONCOS-102 in combination with chemotherapy in malignant pleural mesothelioma.
Targovax ASA, today announces that members of its executive management team is invited to present and participate at upcoming conferences.
Lebrikizumab led to significant improvements with at least 75 percent skin clearance in more than half of people with moderate-to-severe atopic dermatitis (AD), as measured by EASI, in Eli Lilly and Company's (NYSE: LLY) ADvocate 1 and ADvocate 2 Phase 3 clinical trials. In the top-line results from these two studies of lebrikizumab as a monotherapy in AD, primary and all key secondary endpoints, including skin clearance and itch improvement, were met at Week 16. Lebrikizumab is a novel monoclonal antibody (mAb) that binds soluble IL-13 with high affinity, has high bioavailability, a long half-life and blocks IL-13 signaling. 1-4 The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to lebrikizumab for moderate-to-severe AD in adult and adolescent patients (aged 12 to less than 18 years of age and weighing at least 40 kg). Fast Track designation is granted for a medicine that is intended to treat a serious condition and data demonstrate the potential to address an unmet medical need.
Targovax, a clinical stage immune-oncology company, announced that its lead clinical candidate ONCOS-102 has received Fast Track designation in PD-1-refractory advanced melanoma from the United States Food & Drug Administration (FDA).